Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
Filing tables
Filing exhibits
Associated FRES transcripts
FRES similar filings
Filing view
External links
April 30, 2021
Securities and Exchange Commission
100 F Street, N.E.
Washington, DC 20549
Ladies and Gentlemen:
We have read Item 16F of Form 20-F dated April 30, 2021, of AnPac Bio-Medical Science Co., Ltd. (the “Company”) for the fiscal year ended December 31, 2020 and are in agreement with the statements made in the first sentence of paragraph 1, paragraph 2, paragraph 3, paragraph 4, paragraph 5 and paragraph 6 of that section. We have no basis to agree or disagree with other statements of the registrant contained therein.
/s/ Ernst & Young Hua Ming LLP
Shanghai, the People’s Republic of China